Tele: 561.316.3330
Breaking Medical Device News

Wednesday, September 22, 2021
HomeSpark Biomedical Inc.Neurostimulation Device Company Receives $217K NIH Grant to Help Opioid-Addicted Newborns

Neurostimulation Device Company Receives $217K NIH Grant to Help Opioid-Addicted Newborns

Spark Biomedical Reports funds to validate transcutaneous auricular neurostimulation for relieving withdrawal symptoms in infants born with neonatal abstinence syndrome

Spark Biomedical, Inc. is a neurostimulation device company developing solutions for opioid withdrawal.  Today the company announced they received a $217,690 SBIR grant from the National Institutes of Health HEAL initiative. The grant (1R43DA050360-01) will be used to validate the use of neurostimulation to relieve withdrawal symptoms in infants born with neonatal abstinence syndrome (NAS).

The latest National Institute on Drug Abuse statistics estimated 32,000 babies were born with NAS in the United States in 2014, a more than 5-fold increase since 2004. That equates to a baby born every 15 minutes in opioid withdrawal. NAS is a condition where a fetus is exposed to opioids or other substances in the womb and experiences withdrawal symptoms hours after birth. Common symptoms include disturbances in the gastrointestinal, autonomic and central nervous system, leading to a range of symptoms including irritability, high-pitched cry, inadequate sleep and poor feeding.

Spark Biomedical’s neurostimulation solution is a small wearable device that delivers mild electrical stimulation through the skin around the ear, targeting cranial nerve branches. The system is powered by a small rechargeable battery designed to deliver therapy throughout the 10-day treatment period.

The clinical study, expected to commence November 2019, will be overseen by Principal Investigator Dr. Navid Khodaparast, Spark Biomedical’s Chief Science Officer. The Medical University of South Carolina (MUSC) will host the study with Co-Principal Investigators Dr. Dorothea Jenkins, Professor and Neonatologist, and Dr. Bashar Badran, Assistant Professor.

Dr. Khodaparast commented, “The incidence of neonatal abstinence syndrome continues to reach new highs and is too debilitating for us to accept current treatment. We have designed a study that will test a safe, therapeutic option to restore quality of life for infants and ultimately, families. In addition to our adult clinical trial beginning in October, we look to quickly follow with this study and extend the indication into the neonatal segment.”

Dr. Jenkins stated, “MUSC’s vision is to lead health innovation for all the lives we touch, and that means finding new ways of treating clinical conditions that produce higher quality care and better outcomes for our patients. We are very excited to see how this new therapy can help the most vulnerable victims of the opioid crisis overcome withdrawal soon after their birth.”

Daniel Powell, CEO of Spark Biomedical, explained, “These are the most innocent and often overlooked victims of the opioid epidemic, whose first days on earth include experiencing the painful process of withdrawal. The current NAS treatment is to administer either morphine or methadone every few hours to titrate these infants down over a couple of weeks, simply because there are no other options. That, to us, is just not acceptable. If our technology can reduce or prevent the pain as well as the need to use opioids on a newborn, we believe it could give these infants a significantly better start in life and set them on a better path from the beginning.”

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

By using this website you agree to accept Medical Device News Magazine Privacy Policy